How much revenue does Mymetics make?

Mymetics reported 3,000 EUR in revenue for fiscal year 2022, about flat from 3,000 EUR in fiscal year 2021. In Q3 2023 revenue was 0 EUR.

What companies are similar to Mymetics?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Cardax, Inc. (CDXI), Stem Holdings, Inc. (STMH), OncoSec Medical Incorporated (ONCSQ), BC Craft Supply Co. Ltd. (CRFTF).

Mymetics Corporation (MYMX) Stock

About Mymetics Corporation

Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, and malaria. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; and national...

At a glance

Mymetics reported revenue of 3,000 EUR for fiscal year 2022, about flat from fiscal year 2021, and net income of -4.81 million EUR. In Q3 2023 (the quarter ended September 30, 2023) revenue was 0 EUR.

Figures from company filings; latest fiscal year ended December 31, 2022.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.